Remidio’s CE marked and FDA 510k registered retinal imaging devices have helped screen and impact more than 7.5 million patients in 15 countries globally. This is due to increased access provided by the ease of use and affordability of Remidio’s patented optics on the smartphone platform.
Diabetic Retinopathy (DR) is an eye condition causing vision loss and blindness that affects nearly 16.9% of patients with diabetes, 3.6% of whom are most likely to lose their vision because of sight-threatening DR (STDR), according to India’s first National Diabetes and Diabetic Retinopathy Survey in 2019.
